source
- Daraxonrasib uniquely targets active KRAS in pancreatic cancer, says MD Anderson expertDr Shubham Pant, a professor in the Department of Gastrointestinal Medical Oncology at MD Anderson Cancer Center, explained the mechanism of daraxonrasib in a recent commentary. The oral, potent R…
- CellCentric secures $220 million Series D to advance multiple myeloma oral therapyCellCentric, a 22-year-old biotech operating across the Atlantic, announced it has closed a $220 million Series D financing round. The capital will be used to complete development and prepare for…